




# **Transformational Technologies in Biomedical R&D and Healthcare Delivery**

**Dr. George Poste**  
**Chief Scientist, Complex Adaptive Systems**  
**and Del E. Webb Chair in Health Innovation**  
**Arizona State University**  
**480-727-8662 [george.poste@asu.edu](mailto:george.poste@asu.edu)**  
**[www.casi.asu.edu](http://www.casi.asu.edu)**

**Hever 18, Lansdowne, VA**

**4 May 2013**

Slides available @ <http://casi.asu.edu/>



# **The Imperative to Achieve Sustainability in Healthcare: Societal (Economic) and Individual (Wellness)**



**Balancing Infinite Demand Versus Finite Resources  
in an Era of Economic Constraint**

**More Effective Management of Chronic Disease  
in Aging Populations**

**Shift From a “Do More, Bill More”(FFS) Delivery System  
To Integrated Care and Managing Individual Risk to Improve  
Outcomes and Control Cost**


**Technology, Innovation and New Value Propositions**

# Medical Progress: From Superstitions to Symptoms to Signatures




# Mapping The Molecular Signatures of Disease: The Intellectual Foundation of Rational Diagnosis and Treatment Selection


## Genomics





## Proteomics



## Molecular Pathways and Networks



## Network Regulatory Mechanisms




**ID of Causal Relationships Between  
Network Perturbations and Disease**




**Patient-Specific Signals and Signatures of Disease  
or Predisposition to Disease**

# Technology Convergence and Disruption in Healthcare



# **“Thinking Beyond the Pill”**

## **Leveraging Rx Value In Broadened Healthcare Domains**




**Integrated Solutions**

**Integrated Solutions**  
**Rx, Dx, Devices, HIT and ACKM**

# Accelerating Convergence: Conceptual, Technological, Informational and Commercial

**Biomedicine,  
Biotechnology,  
Synthetic  
Biology**



**“Bio-Space”**

**Ubiquitous  
Sensing/  
Devices &  
Social Networks**



**“Connected  
Space”**

**Advanced  
Computing  
and Modeling**



**“Cyberspace”  
and  
“Simulation Space”**

**Neurosciences  
and  
Human-Machine  
Interactions**



**“Cognitive  
Space”**

**Disruptive  
Technologies**



**“Competition  
and  
Opportunity  
Space”**

**New Patterns of Technology Fusion,  
Evolution and Adoption**

**New Knowledge  
Networks**

**New  
Participants**

**New Markets  
and  
Business Models**

# **Transformational Technologies and Major Challenges in Biomedical R&D and Healthcare: Understanding the Design and Control of Complex Networks**

- |   |   |   |
|---|---|---|
| ● (epi)genotype                               | ➔ | ● phenotype (phenomes)  |
| ● molecular networks and cellular specificity | ➔ | ● network perturbation/<br>dysregulation in disease   |
| ● genome engineering networks                 | ➔ | ● cellular reprogramming and synthetic biology  |
| ● brain networks                              | ➔ | ● cognition and behavior<br>● brain machine interface technology  |
| ● digital networks                            | ➔ | ● data-intensive R&D and new knowledge networks<br>● new products and services<br>● social media and healthcare<br>● implications for education, scientific methods |

# **Will Low Cost Whole Genome Sequencing Change Everything?**

**The \$1000 (or less) Whole Genome Sequence (WGS)**

**The \$ ? Interpreted WGS**

**The \$ ? Reimbursed WGS for Clinical Use**

**Techno-optimism and the Seduction of New Technologies:  
Omnipresent Hype and Herd Mentalities**

# Genome Sequencing: The Competitive Landscape is Crowded




# WGS: The Protracted Journey to Routine Clinical Utility in Major Multigenic Diseases?

- closing current ‘holes’ to get to ‘wholes’ (Heidi Rehm)
- still major technical challenges in capturing **complete** and **accurate** WGS
- actionable data
- unraveling complex epistatic and epigenetic events in late-onset multigenic diseases
- size of clinical cohorts needed to validate actionable correlations for regulatory approval
- reimbursement
- ‘the incidentalome’

# The Utility Matrix for Genome Sequencing (2013)

Decision	Single Genes	Gene Panels	WES	WGS
actionable variants	inherited and rare disorders	Rx targets: response/resistance	late onset multi-genic diseases	microbes
	carrier screening	PGx & Rx adverse events		rare diseases
	NIPT	NIPT aneuploidy		
informative but not yet actionable		potential Rx targets but no Rx	multi-genic neurodev. disorders	
			GWAS	
unknown significance				

# WGS and Claims Outstripping Current Analytical Capabilities for Disease Predisposition Risk Profiling (PDx)



# Understanding Genome Organization and Regulation


- **topology**
- **role of non-coding regions and the RNA universe**
- **TF-binding and chromatin states in cell differentiation and disease**

# The Epigenome

**Effect of Maternal  
Diet/Stress/Rx exposure on  
Germ Line Genome  
(+ trans-three-generational?)**



**Modulation of Gene  
Expression/Regulation by  
Environmental Factors, Xenobiotics  
and Rx (The Exposome)**



**International Human Epigenome Consortium**


• • • 1000 reference genomes by 2020



**project blueprint**





- launch September 2011 with €30-million
- map epigenome in 60 human blood cell classes and neoplastic counterparts

# The Complex Interplay Between the Genome, Molecular Networks and Environmental Factors



# Commensal Microbiomes: The “Frenemy Within”

## Metagenome-wide Association Studies (MGWAS)



Immune-Mediated GI Diseases

Type 2 Diabetes Profile

Aging Metabolism and Fragility

Metabolic Activation of Carcinogens/Pollutants


# Make Me.....

**Reprogramming ESCs/iPSCs to Generate Specific Cell Lineages  
as Committed Precursors or End-Stage Differentiated Cells**




**(Re)Building Complex Histotypic Structures with Full Homeostatic Controls**

# Make Me.....




# Master Transcriptional Regulators and Reprogramming Factors in Mammalian Cell Lineages



From: T. I. Lee and R. A. Young (2013) Cell 152, 1237


Validation of (Epi)Genomic Fidelity for Therapeutic Uses

# Analysis of Chromatin-State Landscapes for ESCs/iPSCs, Tissues In Vivo, and Primary Cell Cultures





From: J. Zhu et al. (2013) Cell 152, 642

# Seeding of Autologous Cells Onto Biocompatible Scaffolds to Generate Implantable Organ-Mimetic Structures



# Synthetic Biology: Engineering Microbial Genomes

**Programmable  
Genomes**



**A New Industrial  
Ecology and Novel  
Biosyntheses**

华大基因  
BGI

AGRAQUEST<sup>®</sup>  
better food. better world.™

RoNA  
Therapeutics

MONSANTO   
atlasventure 



 PACIFIC  
BIOSCIENCES™

 Sapphire  
Energy

  
Bayer CropScience

syngenta


 deVGen

 PASTEURIA<sup>™</sup>  
bioscience

BECKER  
UNDERWOOD<sup>®</sup>

 BASF  
The Chemical Company

# Advanced Manufacturing Digital Programming of 3-D Fabrication and New Assembly Technologies




- **digital code for automated assembly of complex multi-scale structures**
- **uncoupling of design from fabrication and rise of point-of-need (PON) production capabilities**
- **3D printing**
  - **spatio-temporal assembly at nano-/ Ångstrom-level scale**
  - **abiotic materials**
  - **biotic materials**
  - **abiotic:biotic hybrids**
- **4D systems**
  - **dynamic behavior of constructed systems**

# Electroceuticals: The Use of Electrical Impulses to Modulate Neural Circuits

## IT'S ELECTRIC


*Electroceuticals deliver electrical impulses targeting the neural circuits that regulate the body's organs and functions.*




**Bioelectronics**

**From: K. Framm et al. (2013) 496, 161**


# Neuro-modulation Devices



# **Sensor World: Biomedicine Meets Materials Science, Engineering and Telecommunications**



# Implantable Microelectrode Arrays for Different Sections of the Nervous System



From: J. Ordóñez et al. (2013) MRS Bulletin 37, 590

# The BRAIN Initiative (2 April 2013)


## Brain Research Through Advancing Innovative Neurotechnologies



# The Brain Initiative: Mapping Neuronal Network Connectivities In Escalating Brain Complexity



**150,000 neurons**



**1 million neurons**



**10 million neurons**



**950 neurons: reconstruction in 5 years**

# A Comparison of High Performance Network Computing: Cortical Simulations at Cat Scale\*




**147,456 CPUs 144 TB Main Memory but still 83x slower firing rate**


**\*Data in R. Ananthanaryanin et al. (2009)  
Proc. IEEE/ACM High Perf. Network Computing**

# Optogenetics

## In Vivo Activation or Inhibition of Neurons Labeled with Microbial Opsin Genes



**Transgenic  
Label Insertion**



**Microelectrode  
Label Insertion**

# 3D Mapping of Brain Structure and CNS Network Functions





- **mapping the complex topologies and excitation patterns in neuronal networks**
- **integration of long-distance regional connectivities and local columnar architectures**



# CLARITY: Lipid Clearing in Acrylamide Infused Whole Brains by SDS and 3D Mapping of Neural Networks



Karl Deisseroth



(Quote from S. R. Y. Cajal)



# Optical Retinal Prostheses



- **artificial stimulation of surviving nerve cells in outer-retinal degeneration of bionic vision restoration**
- **holographic optogenetic stimulation of patterned neuronal activity with millisecond temporal resolution at individual cell scale**

Reutsky-Gefen et.al. (2013) Nature Comm. 4, doi.10.1038/ncomms2500

# “Brain Net”



- first brain-to-brain link via remote transfer of encoded brain pattern to decoder animal and triggering of behavioral mimicry
- build inventory of codes to elicit specific behavior in target (decoder)
  - control of animals
  - design of new control systems for robots
- legal and ethical implications of extension to elicited behavior (control, modulation) of humans

# Brain: Machine Interface Technologies

## Direct Cognitive Control of External Devices



# **Data: The Fastest Growing Resource on Earth**

## **Building an Integrated Healthcare Infocosm**

**Biomedical R&D and Healthcare Delivery as  
Increasingly Data-Intensive Disciplines**

**Managing the Data Deluge**

**The V5 Challenge of Big Data:  
Volume, Variety, Velocity, Verification, Value**




**“The Fourth Site of Care  
is going to be the Internet.”**

**George Halvorson  
CEO, Kaiser Permanente  
Statement at ONC 2012 Annual Meeting**



**134 digital health companies  
each raised \$2M+ in 2012**

# m.Health



**Real Time  
Remote  
Health  
Monitoring  
and  
Chronic  
Disease  
Management**



**Lifestyle  
and  
Fitness**



**Information  
for  
Proactive  
Health  
Awareness  
(Wellness)**

# The Proliferation of Mobile Devices in Healthcare



# Mobile Devices and Telemedicine



# The Quest for Minimally Invasive Monitoring of Multiple Health Status Markers



QUALCOMM  
TRICORDER X PRIZE



# **“The Walk and Die Syndrome:” On Site Monitoring of TBI and Cerebral Hematoma**

- **undetected TBI problem in Iraq/Afghanistan theaters**
- **30% wounded combatants suffered head injury, 40% of which have brain hematomas**



- **OD of hematoma on IR scan differs from normal brain**
- **handheld unit**
- **disposable AA batteries**


**Infrascanner  
200 ADS Medical**



# Geodemographic Information Systems (GIS): Real-Time, Front Line, Ground Zero Data from Field Sampling and Sentinels





# Maintaining Global Preparedness for a High Virulence Pandemic





- April 2013 announcement will now first release new epidemiological data (eg. H7N9) via Twitter


# Miniaturization of Analytical Technologies




**“Lab-on-a-Chip”**




**“Lab-on-a-Tip”**



**“Lab-Always On”  
and  
“Lab-On-Me”**



# **The Measured (Quantified) Self: Real Time Biometrics of Health Status**



**Every Individual Becomes Their Own Control**



- recruitment of 1 million participants
- from profiling every two years (Framingham) to daily monitoring
- longitudinal observational monitoring with every individual acting as own control
- large sample size and avoidance of selection bias
- 1.5% cohort = entire Framingham study (15,000 participants)

# Gray Technologies: Independent But Monitored Living for Aging Populations



**compliance**



**cognitive  
stimulation**



**Fujitsu's 'smart  
walking stick'**

**early alert  
of deterioration**



**use of home  
appliances and lifestyle**

# Robotics: Telemedicine and Home Healthcare



**RP-VITA Remote Presence Robot:  
(iRobot Corp) FDA 501(k) clearance 1/24/13**



# For Trevor Jones: Your Next Acquisition? The Robotic Coach to Improve Your Golf Swing



# Mobile Devices, Sensors and Remote Health Status Monitoring: The Changing 'Care Space' and Improved Continuity in Care Provision

- from fixed, tethered, compartmentalized, provider-centric facilities
- to
- distributed- and virtual-architectures linking multiple providers, home, work and the internet

**expanded 'points-of-touch'  
with the health systems**

**improved continuity  
of care and  
data integration**

- from reactive, incident-centric, poorly coordinated and sequential referrals and inefficient post-incident follow-up(s)

to

- pervasive, persistent monitoring of health status for pre-emptive risk mitigation, improved compliance and personal stewardship of health

# Retail Healthcare: New Services and Value-Based Shopping for Healthcare



# Forging a New Relationship With Patients



- **diabetes self-management program using digital coaching and wireless glucose meter to transmit data to clinical monitors**



- **improve patient outcomes through interactive web application for patients and doctors**
- **initial focus on patients at risk for diabetes and cardiovascular disease**



- **pharmacy-based service in the UK to provide health screenings to prevent heart attack and stroke**



U.S. Department of Health & Human Services

[www.hhs.gov](http://www.hhs.gov)



## Patient Network

Bringing Your Voice to Drug and Device Approval and Safety

Search

Home

About Us

Get Involved

Learn How Drugs & Devices  
Get Approved

Find Out About Clinical  
Trials

Find Other Treatment  
Options

Get Disease  
Information

Learn About the new Web Site

Become a Patient Rep

Make Your Voice Heard

Drug & Device Development



Share your unique perspective and serve on an advisory committee.

Go

Approved  
Drugs at FDA




Find a  
Clinical Trial



Ask the  
FDA



# Patient-Driven Data: Registries, Clinical Trial Enrollment and Observational Outcomes Studies



**From: The Scientist March 2013, p. 36**




# **Social Behavior Becomes Quantifiable**

- **who knows why people do what they do?**
  - **the fact is that they do!**
- **these actions can now be traced and measured with unprecedented precision**
- **with sufficient data, the numbers reveal increasingly predictable behavior individual risk patterns**
- **new business opportunities in multiple sectors including healthcare**
- **new ethical and legal issues regarding privacy and data security**


# **Web-Based Health Information and Research Uses: The Blurring of Informed Consent in Cyberspace**

- **information supplied by the user**
  - **medical history, genomic data, web posts**
- **personal information harvested in interaction with web sites**
  - **IP and e.mail addresses, searches, location data**
- **content that users provide becomes trading capital for web services providers**
- **do browsewrap disclosure agreements (click “I agree”) represent affirmative consent?**


# Data-Intensive Computing, Big Data and New Knowledge Networks in Biomedical R&D and Healthcare Delivery



HELL IS THE PLACE WHERE NOTHING CONNECTS — T.S. ELIOT



# The Need for Facile, Seamless Data Exchange Formats for Large Scale Biomedical Data Systems



# Healthcare Data and EMR/EHRs Not Designed for Facile Mining or the Integration of New Data Classes (Omics)



Data Tombs

# **Design of Agile EHR/EMR Formats for New Data Classes and Large Scale Data Mining**

- **EMR/EHR as e.replicant of paper records**
- **the vendor trap and incompatible formats**
- **rigid design formats and limited agility to integrate/mine new data classes (e.g. omics, social media)**
- **privacy and security protections as barriers to large scale mining and analytics, and of observational data**

# Formation of the CommonWell Health Alliance (March 2013)

## A Major Step in the Interoperability in Health IT






## Health Outcomes Mining From Large Clinical Datasets



- 100 million claims records
- 5 million clinical records



# Natural Language Processing, 'Trained Systems' and Big Data Analytics



# Rich Data Will Drive Clinical Profiling to 'Interpreted Phenotypes'



## Observed Phenotype

- clinical annotation
- EHR data mining

## Interpreted Phenotype and Phenomes Via Multi-Parameter Integration

- large scale data analytics for "*robustness of match*"
- reported clinical phenotype
  - + integrated personal Omics profile
  - + population EMR data mining
  - + curated literature
- automated decision-support


# Data Changes the Questions That Can Be Asked



**Isolated  
Data**



**Complex  
Networked  
Data**



**Complex  
Computational  
Data**


# The Omics Data Storage Challenge

(J. Starren et al. 2013 JAMA 309, 1237)

- **typical EHR**
  - 375 KB/patient
- **radiologic picture archiving and communication system (PACS)**
  - 104 MB/patient
  - x277 > EHR
- **WGS**
  - 3-10 million variants/individual
  - 5-10 GB/individual
  - x50 > imaging



**“If the scientific community can justify billions of dollars, 100MW of power and thousands of staff in order to fire tiny particles that most people have never heard of around a big ring of magnets for a fairly narrow science purpose that most people will never understand.....**



**.....then how come we can't make the case for facilities needing half the resources that can do wonders for a whole range of science problems and industrial applications?”**

**Andrew Jones  
Vice-President, Numerical Algorithms Group  
HPC Wire 29 August 2011**




**21st Century Knowledge Networks  
versus  
20th Century Organizations**

# The Pending Era of Cognitive Systems: Overcoming the “Bandwidth” Limits of Human Individuals




- **limits to our expertise**
- **limits to our multi-dimensionality**
- **limits to our sensory systems**
- **limits to our experiences and perceptions**
- **limits to our objective decision-making**

# Data Customization and Visualization for EMRs




# Computing Systems and Interactive Displays: From Defense to Gaming to Interactive Dynamics for R&D and Business Processes



# Pervasive Computing: The Next Major Transition?



# A Leap Forward: 3D Gestural Interfaces



classroom emulation

# Does Anyone Read Printed Journals Anymore?

PHILOSOPHICAL  
TRANSACTIONS:  
GIVING SOME  
ACCOMPT  
OF THE PRESENT  
Undertakings, Studies, and Labours  
OF THE  
INGENIOUS  
IN MANY  
CONSIDERABLE PARTS  
OF THE  
WORLD

Vol I.

For Anno 1665, and 1666.

In the SAVOY,  
Printed by T. N. for John Martyn at the Bell, a little with-  
out Temple-Bar, and James Allestry in Duck-Lane,  
Printers to the Royal Society.

nature

THE INTERNATIONAL WEEKLY JOURNAL OF SCIENCE

The transformation of scientific publishing PAGE 425



A NEW PAGE

# Technology Acceleration and Convergence: The Escalating Challenge for Professional Competency, Decision-Support and Future Education Curricula

**Data Deluge**



**Cognitive Bandwidth Limits**



**Automated Analytics and Decision Support**



**Facile Formats for Actionable Decisions**

# From Bench to Keyboard For Second Opinion, Consult a Computer?



# Regulatory Science

## STRATEGIC PRIORITIES 2011 – 2015



Responding to  
the Public Health  
Challenges  
of the 21<sup>st</sup> Century



OCTOBER 2011

[www.fda.gov/innovation](http://www.fda.gov/innovation)

## Driving Biomedical Innovation:

Initiatives to Improve  
Products for Patients



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
U.S. FOOD AND DRUG ADMINISTRATION

A STRATEGIC PLAN  
AUGUST 2011

[www.fda.gov/regulatoryscience](http://www.fda.gov/regulatoryscience)

## Advancing Regulatory Science at FDA



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
U.S. FOOD AND DRUG ADMINISTRATION



BioIT World 2011 - by **Sorena Nadaf, M.S. M.M.I**  
*Director - Translational Informatics, CIO*

# **“Outside In” Data and Processes Will Intensify as Drivers of Disruptive Change in Healthcare Delivery**



- from Rx product sales to optimizing Rx value in health outcomes/cost control
- patient engagement and loyalty
- integration with MDx, devices, m.health and real time remote health status monitoring
- health data aggregation and mining of large scale observational studies of real world use

# **Mastery of Technology Convergence, Big Data and Understanding Complex Networks**

**Building New Knowledge Networks: Who Knows Wins!**

**Building New Coalitions: Who Disrupts Current  
Pervasive Inefficiencies in Healthcare Wins!**

**Building New Rx Value Propositions: Who Integrates  
Rx With Other Healthcare Services More Proficiently Wins!**

# Transformational Technologies and New Value Propositions in Healthcare

## Technology

- understanding information patterns in complex systems
  - biological networks
  - care delivery networks
  - intelligent data networks
- integration of RX, MDx, sensors, devices and HIT

## Value Drivers

- creating value outside the Rx product
- health outcomes, cost control
- consumer: patient engagement and loyalty
- the wellness premium
- increasing power of patients and payors

# The Principal Forces Shaping Biomedical R&D and Healthcare Delivery

- MDx, sensors

**device-based  
medicine**

- remote health monitoring
- telemedicine

**molecular (precision)  
medicine**


- integrated analytics of biological networks

**information-based  
healthcare**

- m.health/e.health
- data- and evidence- based decisions and Rx selection

**outcomes-based  
healthcare and sustainable health**

**new value propositions, new  
business models and services**



# Precision Medicine: Understanding Network Biology as the Intellectual Foundation for the Evolution of Robust Biological Knowledge and Rational Medicine



**“Scientia potentia est”  
(Knowledge is  
power)**

**Experimental  
Design**



**“Nullius in verba”  
(Take nobody’s  
word for it)**

**Standards  
and  
Reproducibility**



**“Omnis sarta est”  
(Everything is  
connected)**

**Mapping  
Network  
Dynamics**



**0011010100110....  
(Code is power)**

**Precision  
Medicine**



**“Oh, God help us!  
We’re in the hands of  
engineers.”**

**Dr. Ian Malcolm  
‘Chaotician’: Jurassic Park**

Slides Available: <http://casi.asu.edu/>

